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Patients with chronic kidney disease treated by in-center
conventional hemodialysis (3 times per week) have
significant impairments in health-related quality of life
measures, which have been associated with increased
morbidity and mortality. FREEDOM is an ongoing prospective
cohort study measuring the potential benefits of at-home
short daily (6 times per week) hemodialysis. In this interim
report we examine the long-term effect of short daily
hemodialysis on health-related quality of life, as measured by
the SF-36 health survey. This was administered at baseline,
4 and 12 months after initiation of short daily hemodialysis
to 291 participants (total cohort), of which 154 completed
the 12-month follow-up (as-treated cohort). At the time
of analysis, the mean age was 53 years, 66% were men,
58% had an AV fistula, 90% transitioned from in-center
hemodialysis, and 45% had diabetes mellitus. In the total
cohort analysis, both the physical- and mental-component
summary scores improved over the 12-month period, as did
all 8 individual domains of the SF-36. The as-treated cohort
analysis showed similar improvements with the exception of
the role-emotional domain. Significantly, in the as-treated
cohort, the percentage of patients achieving a physical-
component summary score at least equivalent to the general
population more than doubled. Hence, at-home short daily
hemodialysis is associated with long-term improvements in
various physical and mental health-related quality of life
measures.
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The impaired health-related quality of life (HRQOL) of
patients with chronic kidney disease treated by conventional
three times weekly hemodialysis (HD) is well documented1–6
and has been an area of major concern for patients, their
families, and nephrologists. The Center for Medicare and
Medicaid Services now mandates that dialysis facilities in the
United States perform an annual measurement of HRQOL for
dialysis patients, preferentially using the Kidney Disease
Quality of Life-36 (KDQOL-36) questionnaire with additional
instruments as clinically indicated (http://www.cms.hhs.gov/
cpmproject). A major challenge for nephrologists is how to
respond to these quality of life measurements, and what
strategies, if any, can be implemented to improve the lives of
dialysis patients.
This is an area that has been attracting much interest
recently, as there is increasing recognition of the importance of
HRQOL measurements.1–6 Results from the Dialysis Out-
comes and Practice Patterns Study (DOPPS) showed that
reduced scores in patients undergoing in-center three times
weekly HD using generic HRQOL instruments, such as the
Short Form-36 (SF-36) health survey, are associated with
significantly higher hospitalization rates and mortality.1
Specifically, the physical-component summary (PCS) and
mental-component summary (MCS) scores of the SF-36 were
associated with a 25 and 13% risk increase in mortality per
10-point drop, respectively. The corresponding hospitalization
risk increase was 15 and 6%, respectively.1 These important
observations were substantiated by a more recent study with
very similar findings examining outcomes in over 40,000
patients.6
Improvement in a variety of HRQOL measures has been
observed in several small studies among patients receiving
more frequent (more than three times weekly) HD.4,7–9 These
preliminary findings have, to some extent, been confirmed in
more recent, larger cohort studies as well as in randomized
controlled trials. In the Frequent Hemodialysis Network
(FHN) trial, patients randomized to in-center short daily
HD prescribed six times per week experienced significant
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improvement in the physical-health composite (PHC) score of
the RAND 36-item health survey10 compared with those
maintained on in-center three times weekly HD. Indeed, at 12
months, the frequent HD-treated group reported an increase
in the adjusted mean PHC score of 3.3 points, compared to a
change of only 0.2 in the conventional HD-treated group.11
The FREEDOM (Following Rehabilitation, Economics
and Everyday-Dialysis Outcome Measurements) Study is an
ongoing US-based observational study examining the
potential clinical and economic benefits of at-home short
daily HD.12 We have previously demonstrated that short daily
HD is associated with a sustained improvement in depressive
symptoms, quality of sleep, prevalence and severity of restless
legs symptoms, and post-dialysis recovery time.12,13 In this
interim report, as part of an a priori planned analysis, we
examine the long-term effect of short daily HD on HRQOL,
as measured by the SF-36 health survey.
RESULTS
Derivation of the cohort
Between 23 January 2006 and 31 December 2009, a total of
312 study participants were enrolled from 33 sites, of which
13 participants were excluded due to consent withdrawal or
study ineligibility. Of the remaining 299 participants, 291
completed the SF-36 health survey at enrollment. Of the 291
participants included in this analysis, 137 discontinued study
therapy before 12 months, of which 74 occurred before 4
months. Reasons for study discontinuation included kidney
transplantation (n¼ 14), transfer out of participating dialysis
center (n¼ 7), death (n¼ 13), modality change/return to
in-center dialysis (n¼ 63), off short daily HD for 46 weeks
(n¼ 12), recovery of kidney function (n¼ 2), non-compli-
ance (n¼ 3), and other (n¼ 23). The remaining 154 partici-
pants completed 12 months of follow-up, and constituted the
as-treated cohort.
Characteristics of the cohort
Table 1 displays the enrollment characteristics of the total
cohort (291 participants) included in this report, stratified by
the baseline PCS and MCS score tertiles. Mean age was 53
years, 66% were men, 70% were white, 45% were diabetic,
90% had hypertension, 27% had a history of congestive heart
failure, and 58% had an arteriovenous fistula. Mean duration
of dialysis was 3.6 years, and residual urine volume 365 ml/
day. Overall, 5% of participants required assistance with daily
activities, and 3% were unable to ambulate. In terms of
psychotropic drugs, 19% of participants were prescribed
anxiolytics/muscle relaxants, 16% hypnotics, 37% analgesics,
and 25% anti-depressants. Participants in the upper baseline
PCS score tertile were younger (P¼ 0.007) and healthier, as
evidenced by a lower body mass index (P¼ 0.02), a lower
prevalence of comorbidities (e.g., diabetes, and heart failure),
a higher prevalence of arteriovenous fistula use (P¼ 0.003), a
higher serum creatinine (Po0.001) and albumin (P¼ 0.002),
a lower requirement for assistance with daily activities
(Po0.003), and a higher ability to ambulate (P¼ 0.002).
By contrast, participants in the upper baseline MCS score
tertile were older (P¼ 0.007), and had a lower prevalence of
anti-depressant use (P¼ 0.02) and lower serum phosphorus
(P¼ 0.03).
There were no significant differences in the baseline
characteristics between patients who dropped out before 12
months and those who completed 12 months of follow-up,
with the exception of a lower serum creatinine (8.3±3.6 vs.
9.3±3.8 mg/dl; P¼ 0.04) and albumin (3.7±0.5 vs. 3.9±
0.4 g/dl; P¼ 0.007), and a higher prescription of analgesics
(44 vs. 32%; P¼ 0.04) among patients who dropped out
compared with those who did not (Supplementary Table
online). Participants who discontinued the study before
month-12 had significantly lower baseline MCS scores com-
pared with those who completed 12 months (43±13 vs. 49±12;
Po0.001). Although the baseline mean PCS score was not
significantly different between the two groups (34±10 vs.
35±11; P¼ 0.6), those who discontinued the study before
month-12 had lower scores on most of the individual SF-36
domains, including role physical (P¼ 0.05), bodily pain
(P¼ 0.07), general health (P¼ 0.03), vitality (P¼ 0.03), role
emotional (Po0.001), mental health (Po0.001), and social
functioning (P¼ 0.02).
Short daily HD treatment characteristics
For the total cohort, the mean training period required to
transition to short daily HD was 26±34 days. The initial
prescribed dialysate volume was 21±4 l/session, with a
prescribed blood flow rate of 462±59 ml/min, and a flow
fraction ((blood-to-dialysate flow rate ratio) 100) of 33±3%.
The dialysate lactate concentration was 43±3 mEq/l. There
were no differences in these parameters among patients who
completed 12 months of follow-up and those who did not
(data not shown).
Effect of short daily HD on the SF-36 health survey
As shown in Figure 1, short daily HD resulted in a sustained
improvement in the PCS score at 4 and 12 months (global
Po0.0001), after adjustment for the use of psychotropic
medications. Indeed, in the as-treated cohort (Figure 1a), the
adjusted mean PCS score increased by 4 points at month-4
(Po0.0001) and month-12 (Po0.0001) compared with
baseline. These findings were attenuated but remained robust
in the total cohort (Figure 1b) with an adjusted mean PCS
score increase of 3 points at month-4 (Po0.0001), and 4
points at month-12 (Po0.0001). Similarly, over the 12-
month period, there was significant improvement in the
mean adjusted scores of all six PCS domains in the as-treated
cohort (Figure 1a), including scales related to physical
functioning (Po0.001), role physical (Po0.0001), bodily
pain (P¼ 0.04), general health (Po0.0001), vitality
(Po0.0001), and social functioning (Po0.0001). Results
were similar for all six PCS domains in the total cohort
(Figure 1b). In a sensitivity analysis adjusting for the number
of participants per study site, the change in the PCS score
remained significant, with an improvement in the mean score
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by four (95% confidence interval 2, 5) points at 4 and 12
months, respectively (Po0.0001).
Although short daily HD resulted in a sustained
improvement in the MCS score over the study course in
both the as-treated (Figure 1a, global P¼ 0.02) and total
(Figure 1b, global P¼ 0.0001) cohort, the increase was less
than that observed for the PCS scores. In the as-treated
cohort, the adjusted mean MCS score increased by only 2
points at month-4 (P¼ 0.005) and month-12 (P¼ 0.08),
compared with the baseline value of 50. A similar trend was
observed in the total cohort, with scores increasing by 3
points at month-4 (P¼ 0.005) and 2 points at month-12
(P¼ 0.08). In both analyses, among the two MCS-specific
domains, the adjusted mean mental health score significantly
improved by 4–6 points at month-4 (Po0.01) and by 4
points at month-12 (P¼ 0.01), whereas the role-emotional
scale displayed no significant improvement.
In the as-treated cohort, the proportion of participants
with a PCS scoreX50 (a cut-off representing the mean score
observed in the general US population) more than doubled,
increasing from 9% at baseline to 21% at month-12
(Po0.001; Figure 2a). However, the percentage of partici-
pants with an MCS score X50 did not significantly change
over the 12-month period (P¼ 0.2; Figure 2b). In the total
cohort, the proportion of participants with a PCS scoreX50
increased from 8% at baseline to 20% at month-4 (Po0.001)
and 24% at month-12 (Po0.001; Figure 2a). However, the
percentage of participants with an MCS score of X50
increased from 47% at baseline to 57% at month-4 (P¼ 0.03)
and 64% at month-12 (P¼ 0.001; Figure 2b).
Figure 3 displays the 12-month change in the adjusted
mean PCS score, stratified by baseline PCS tertiles. In the as-
treated and total cohort, participants in the lowest baseline
PCS tertile group (o30 ando29 for the as-treated and total
cohort, respectively), suggestive of the poorest physical
health, experienced the greatest improvement in the adjusted
mean PCS score. Indeed, in tertile-1, the PCS score improved
by 6–7 points (Po0.001) at month-12, compared with only a
4-point improvement in tertile-2 (Pp0.03). Tertile-3 experi-
enced no further improvement in PCS score. In a separate
sensitivity analysis aimed at examining change in the PCS
score after adjustment for number of comorbidities or the
baseline PCS score, the 12-month adjusted mean PCS score
improvement remained significant in both the as-treated and
total cohort (data not shown).
DISCUSSION
One of the major challenges for nephrologists is developing
strategies to manage the impaired HRQOL measures
reported by dialysis patients. Although these impairments
are well documented, how to systematically address and
improve the HRQOL in dialysis patients has received far too
little attention. The present study reports on the interim
results of the FREEDOM using data from the SF-36 health
survey in patients completing 4 and 12 months of at-home
short daily (six times per week) HD with a targeted standardT
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Kt/Vurea of 2.0. Psychometric studies performed in dialysis
patients have shown the widely used SF-36 health survey to
be a reliable and valid measure of HRQOL.14 It is a generic
measure, as opposed to one that targets a specific age, disease,
or treatment group. Accordingly, the SF-36 has been useful in
comparing the relative burden of diseases, and differentiating
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Figure 1 | Effect of short daily hemodialysis on the SF-36 health survey (eight domains and two summary measures) at 4 and
12 months. The results are displayed for the as-treated cohort (a; n¼ 154) and the total cohort (b; n¼ 291). The data are presented
as adjusted mean (95% confidence interval) derived from a random-effects mixed model. Adjustment variables include use of anxiolytics,
hypnotics, anti-depressants, and analgesics (at any time both for the as-treated and total cohort), time, and dropout (for the analysis
of the total cohort only). PCS denotes physical-component summary; and MCS, mental-component summary. For each domain and
summary measures, the global score statistic P-value is reported.
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Figure 2 |Percentage of study participants with mean physical-component summary (PCS)þmental-component summary (MCS)
score X50. Percentage of study participants with PCS (a) and MCS (b) score X50 (normal mean score for US population) at baseline and
after 12 months of short daily hemodialysis in the as-treated (n¼ 154) and total (n¼ 291) cohort. The P-values are derived from the
McNemar test. *Po0.001 vs. baseline; wP¼ 0.001 vs. baseline.
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the health benefits produced by a wide range of treatment
strategies.15
To our knowledge, the FREEDOM study is the largest
prospective cohort study of short daily HD delivered at home.
In the present interim report, this study demonstrates that
over a 12-month period, the initiation of at-home short daily
HD, primarily in a prevalent HD population, results in broad
and sustained improvement in the majority of the SF-36
scores. The increases were most dramatic for the physical
domains, including the PCS and the six domains that
contribute to the PCS score. These improvements were
observed after adjustment for the use of several psychotropic
drugs, including hypnotics, anxiolytics, anti-depressants, and
analgesics. A switch to short daily HD resulted in a clinically
meaningful PCS score improvement of 4 points, which was
consistent with our hypothesized effect estimate,12 and was
independent of comorbidities. Furthermore, the greatest
improvement in the PCS score was observed in the lowest
baseline PCS tertile group (score of less than 29 to 30), where
there was a gain of 6–7 points in both the as-treated and total
cohort. In addition, the proportion of patients reporting PCS
scores of 50 or greater (50 being the average value observed
in the general US population) more than doubled over the
12-month study period, suggesting an overall improvement in
physical health. The study findings are important, as dialysis
patients with reduced PCS scores have worse clinical out-
comes, with regard to mortality and hospitalization rates.1,6
Despite the strong association of PCS scores with adverse
outcomes, few studies have examined strategies to improve
these measures as a potential means to enhance patient
survival. Thus, the findings in this study are particularly
important, and the sustained improvement at 12 months of a
statistically significant 4-point increase in mean PCS score is
especially noteworthy.
Changes in the mental and emotional domains of the SF-
36 were noted as well, but the changes were not as impressive
as for the physical domains. Indeed, compared with baseline
values, the MCS scores significantly improved at month-4,
but not at month-12, although the global P-value for the
trend analysis was significant. Of note, the baseline MCS
score of the group that completed the 12-month follow-up
period (mean score of 50) was the same as that observed in
the general US population.15 Significant increases, however,
were observed in four of the five domains that contribute to
the MCS score at both 4 and 12 months. Furthermore,
previous data from the FREEDOM study indicated signifi-
cant improvement in depression scores,16 suggesting a positive
emotional impact of treatment change with more frequent
home HD.
Studies that have looked at the changes that occur in
HRQOL measures with institution of short daily HD have
generally shown an improvement in a variety of selected
domains. However, many of these studies have been limited
by small sample sizes, lack of control groups, and the
variability in the delivered dose of dialysis. The results of the
FHN trial are, therefore, of particular interest.11 In this
controlled trial, patients randomized to in-center short daily
HD (prescribed six times per week, with an achieved
standard Kt/Vurea of 3.6), as compared with patients on
conventional three times weekly in-center HD, were noted to
have significant improvements at 12-months in the RAND-
36 PHC score. Although the scoring of the PHC and PCS
is slightly different, it is noteworthy that the increment of
the PHC in the FHN trial and the PCS in this study were
of similar magnitude (about 3–4 points). However, it is
important to note that the treatments in the two studies were
different—the FHN trial treated patients in dialysis centers
with a standardized Kt/Vurea of 3.6, whereas the FREEDOM
study treated patients at home with a standardized Kt/Vurea
of 2.0–2.1.
How should clinicians interpret the changes in the HRQOL
scores with the modification in the dialysis treatment
regimen? There is considerable controversy concerning what
constitutes a ‘meaningful’ change in HRQOL scores. Some
investigators find this concept problematic and have suggested
that an improvement in patient reported quality of life, of
whatever magnitude, may be important for the indivi-
dual.17,18 It is important to note that in our initial paper
describing the methodology of the FREEDOM study,12 we
indicated that we were focusing attention on a 3–5 point
increase in the PCS score based on previously published data.
An interesting observation in this study is that patients who
did not complete the study, compared to those who did,
scored lower on MCS and various individual SF-36 domain
scores. This is an area that deserves further exploration. We
can only speculate as to whether patients with lower scores are
at greater risk for daily HD technique failure, and therefore
might require targeted interventions and closer monitoring by
health-care providers to help mitigate this risk.
Strengths of this interim analysis include a large number
of participants recruited from 36 sites, the use of a well
recognized, validated survey to assess physical and mental
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Figure 3 | Twelve-month change in the adjusted mean
physical-component summary (PCS) score according to the
baseline PCS tertiles. The results are displayed for the as-treated
(n¼ 154) and total cohort (n¼ 291). The data are derived from a
random-effects mixed model, and adjustment variables include
use of anxiolytics, hypnotics, anti-depressants, and analgesics (at
any time both for the as-treated and total cohort), time, and
dropout (for the analysis of the total cohort only). *Po0.001;
wP¼ 0.03; 4P¼ 0.01.
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HRQOL, and the 12-month follow-up. The results remained
robust in both the as-treated and total cohort. It should be
emphasized that this study extends previous observations
from the FREEDOM study documenting significant im-
provements in several other HRQOL indicators, including
depressive symptoms, post-dialysis recovery time, restless legs
symptoms, and sleep disturbances.13,16
Study limitations include selection biases that are evident
by the recruitment of a relatively younger patient population
when compared with the typical US dialysis population.
However, 28% of patients had a central venous catheter for
vascular access, 45% were diabetic, and 27% had a history of
heart failure, suggesting that the cohort was not necessarily
healthier. Although the study experienced a high attrition
rate, characteristics of the participants who dropped out did
not differ from those who completed 12 months of follow-up
with the exception of poorer nutritional biochemical markers
and lower MCS scores. Although the absence of a control
group is an important limitation, it should be emphasized
that the observed improvement persisted beyond 4 months,
arguing against the potential for regression to the mean. To
what extent the improvement in HRQOL is the consequence
of more frequent HD, as opposed to the location of the
therapy in the home setting, cannot be ascertained from this
study, although the FHN trial, which was conducted in-
center, also demonstrated significant improvements in the
PHC scores. Finally, although the as-treated and total cohorts
were similar on the measured characteristics, some poten-
tially important unmeasured characteristics are not accounted
for including differences in psychosocial support and com-
mitment of the family caregiver.
In conclusion, the present interim report of the FREE-
DOM study demonstrates that initiation of short daily HD at
home is associated with significant and clinically meaningful
improvement in HRQOL, as measured by the SF-36 health
survey. Whether these changes are associated with a decline
in hospitalizations or an improvement in survival remains to
be determined.
MATERIALS AND METHODS
Study design and setting
This was a multi-center, prospective, cohort study of at-home short
daily HD with a planned 12-month follow-up (ClinicalTrials.gov
identifier, NCT00288613).12 Eligible patients were adults (age X18
years) with end-stage renal disease requiring dialysis who were being
initiated on short daily HD (prescribed six times per week) at home
and who had Medicare as their primary insurance payer. Exclusion
criteria included current use of the device, prior enrollment in the
study, current enrollment in an investigational drug or device trial that
might impact the outcome measures, and low likelihood of surviving
the first 4–6 weeks encompassing the training period. Written
informed consent was obtained from all study participants. A central
or local institutional review board approved the study protocol.
Short daily HD prescription
Short daily HD was delivered using the NxStage System One cycler
(NxStage Medical, Lawrence, MA, www.nxstage.com). This device
incorporates a high-flux polyethersulfone dialyzer and relies on an
inverse dialysate-to-blood flow rate ratio of 1-to-3 compared with a
conventional dialysis machine, which uses a 2-to-1 ratio. Lactate-
based dialysate was delivered either in premixed, sterile, non-
pyrogenic dialysate fluid bags or through an ultrapure water
purification system (PureFlow SL, NxStage Medical). The initial
prescription targeted a single pool Kt/Vurea of 0.45–0.50, based on six
treatments per week, using the Daugirdas 2nd generation equation.19
This corresponded to a weekly standard Kt/Vurea of 2.0–2.2, meeting
or exceeding the recommended threshold of 2.0.20
Data collection
At enrollment, data collection included demographic information,
comorbid conditions, duration of dialysis, dialysis prescription
parameters (including Kt/Vurea), vascular access type, prior renal
replacement therapy, and laboratory data (average of three record-
ings). A 24-hour timed urine collection was also obtained to assess
residual urine volume. Data on prescribed psychotropic medications,
including the use of anxiolytics, hypnotics, anti-depressants, and
opioid analgesics, were collected at enrollment, and at 4 and 12
months. A variety of HRQOL surveys were also obtained over the
course of the study, which have previously been reported.13,16
Self-administration and scoring of the SF-36 health survey
HRQOL was assessed at enrollment and at 4 and 12 months of
follow-up by self-administering the SF-36 health survey (Medical
Outcomes Trust, Boston, MA). This multipurpose self-reported
measure of HRQOL has been widely used, and validated for use in
both the general population and dialysis patients.14,21,22
The SF-36 comprises 36 questions and yields an 8-scale profile
that is integrated into two summary measures, the PCS and
MCS.15,22 The PCS includes dimensions of the physical functioning,
role-physical, bodily pain, and general health scales, as well as
elements of the vitality and social functioning scales. The MCS is
comprised of the role-emotional, and mental health scales, and also
includes elements of the general health, vitality, and social
functioning scales.15,22 The survey results were scored using version
2 of the SF-36 health survey software (SF-36v2 Health Survey).
Aggregate PCS and MCS scales are standardized to have a
mean±standard deviation of 50±10 in the average US popula-
tion.15 Normalization of the PCS and MCS scores over the study
period was defined by a score of greater than 50.
Statistical analysis
Continuous variables are presented as mean (±standard deviation)
or median (with interquartile range), and categorical variables as
number (with percentage). For this analysis, an a priori sample size
calculation was performed to assess the change in the PCS score at
the 12-month time point to achieve 80% power for a two-sided test
with type-I error of 0.05, assuming a drop out rate of 30%.12 A
minimum sample size of 153 was calculated based on a mean
(±standard deviation) PCS score improvement of 4±10 units.21,23
Baseline characteristics were compared using the unpaired t-test
or w2-test. For variables measured over 2 time points, comparisons
were made by paired t-test or signed rank test, as appropriate and
the McNemar test (test of symmetry).
Analyses were performed on the as-treated and total cohort to
examine the effect of short daily HD on SF-36 scores, including the
PCS, MCS, and the eight individual domains. The as-treated cohort
was restricted to study participants who completed 12 months of
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follow-up. The total cohort included all participants irrespective of
early study discontinuation. For this conservative analysis, we
applied a pattern-mixture model,24 whereby an indicator variable
(dropout¼ 1, 12-month study completion¼ 0) was introduced with
the assumption that study participants who dropped out had
different outcomes by a constant amount compared with those who
completed the study. As an estimate of missing data pattern, the
proportion of dropout of this study sample (0.47, 137/291) was
used, and then the predicted means were obtained by averaging this
over the dropout pattern.
For both analyses, we used mixed models to examine improve-
ments in summary and individual SF-36 scores over 12 months, and
included use of anxiolytics, hypnotics, anti-depressants, and
analgesics as fixed factors, and each subject’s intercept and slopes
due to time as random factors. These analyses were adjusted for the
use of psychotropic drugs to account for the potential confounding
effect of these drugs on changes in the individual and summary
components of the SF-36 health survey. In sensitivity analyses
examining changes in the PCS score, the models were adjusted for
the baseline PCS score, number of comorbidities, or number of
participants per study site (o5, 5–10, and 410 participants).
The results are displayed as adjusted means with 95% confidence
interval. All statistical analyses were performed using SAS version
9.2 (SAS Institute, Cary, NC). Differences were considered
statistically significant at Po0.05.
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Appendix
FREEDOM Study Group
The following FREEDOM Study investigators enrolled at
least one subject as of 31 December 2009: Mirel Abramovici,
MD (Renal Center of Westwood, Westwood, NJ); Sujatha
Addagatla, MD (Apollo Healthcare, Niagara Falls, NY);
George Aronoff, MD (University of Louisville, Louisville,
KY); John Burkart, MD (Wake Forest University/Piedmont
Dialysis, Winston-Salem, NC); Prakas D’Cunha, MD (Renal
Advantage Inc., Palm Harbor, FL); Rachid Daoui, MD
(Hortense & Louis Rubin Dialysis Center, Clifton Park,
NY); William Elliott, MD (DaVita Bluemound Dialysis,
Wauwatosa, WI); Claude Galphin, MD (Nephrology Associ-
ates, Chattanooga, TN); Todd Gehr, MD (Virginia Com-
monwealth University/Renal Advantage Inc., Richmond, VA);
Martin Gelman, MD (Personal Dialysis, Inc., Brighton, MA);
Michael S Gersch, MD (Arkansas Nephrology Research
Associates, Hot Springs, AR); Tim Govaerts, MD (Dialysis
Center of Lincoln, Lincoln, NE); Troy Plumb, MD (Uni-
versity of Nebraska/Renal Advantage Inc., Omaha, NE);
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Andrea Iannuzzelli, MD (Silver Care Dialysis, Cherry Hill,
NJ); Heidi Joist, MD (Renal Advantage Inc., Frontenac, MO);
Michael A Kraus, MD (Indiana University, Indianapolis, IN);
Pius Kurian, MD (DaVita Midwest, Fairborn, OH); Janice
Lea, MD (Emory University Dialysis, Renal Care Partners,
Sandy Springs, GA); Brent W Miller, MD (Washington
University/Barnes Jewish Dialysis Center, St Louis, MO);
Chandra Mohan, MD (Wellspan Dialysis, York, PA); James
Novak, MD (Henry Ford Hospital/Greenfield Health, De-
troit, MI); James Porile, MD (Nephrology Inc., Mishawaka,
IN); Dana Rabideau, MD (Fort Smith Regional Dialysis, Fort
Smith, AR); Victor Rozas, MD (Great Lakes Renal Network,
Alma, MI); Ahmet Sevimli, MD (Munson Dialysis, Traverse
City, MI); Marvin Sinsakul, MD (Circle Medical Manage-
ment, Chicago, IL); Brigitte Schiller, MD (Satellite Health-
care, San Jose, CA); Scott Solcher, MD (Kansas Dialysis
Services, Topeka, KS); Robert Szewc, MD (Barlite SW Kidney,
San Antonio, TX); Isaac Teitelbaum, MD (University of
Colorado, Aurora, CO); Kant Tucker, MD (Kidney Centers,
Inc., Simi Valley, CA); Amy Williams, MD (Mayo Clinic,
Rochester, MN); and Bessie Young, MD (Northwest Kidney
Centers, Seattle, WA).
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